Furthermore, SAMHD1 has been shown to modulate in vitro efficacy of several antinucleoside metabolite drugs used in the treatment of viral infections or cancer, either improving its action by depleting the intracellular pool of dNTP competitors [18,19] or limiting its action by directly using the triphosphate compounds as substrates, as in the case of cytarabine (Ara-C), which is the standard treatment for acute myeloid leukemia (AML) [20,21]. Here, SAMHD1 is linked to cancer.